Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238

Cancer Research

Volumn 59, Issue 8, 1999, Pages 1947-1953

  Plonowski, Artur ^a   Schally, Andrew V ^b   Nagy, Attila ^c   Baodong, Sun ^c   Szepeshazi, Karoly ^c  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HORMONAL CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; TUMOR VOLUME;

ANDROGENS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; GENE EXPRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PYRROLES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033561724     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
2. Potosky, A. L., Miller, B. A., Albertsen, P. C., and Kramer, B. S. The role of increasing detection in the rising incidence of prostate cancer. J. Am. Med. Assoc., 273: 548-552, 1995.
3. Schroeder, F. H., and Boyle, P. Screening of prostate cancer: necessity or nonsense? Eur. J. Cancer, 29A: 655-661, 1993.
4. Huggins, C., and Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941.
5. Sogani, P. C., and Fair, W. R. Treatment of advanced prostatic cancer. Urol. Clin. N. Am., 14: 353-371, 1987.
6. Schally, A. V., and Comaru-Schally, A. M. Hypothalamic and other peptide hormones. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. E. Kufe, D. L. Morton, and R. R. Weichselbaum (eds.). Cancer Medicine, 4th ed., pp. 1067-1086. Baltimore: Williams and Wilkins, 1997.
7. Yagoda, A., and Petrylak, P. D. Cytotoxic therapy for advanced hormone-resistant prostate cancer. Cancer (Phila.), 71 (Suppl. 3): 1098-1109, 1993.
8. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160: 1220-1229, 1998.
9. Sivam, G. P., Martin, P. J., Reisfeld, R. A., and Mueller, B. M. Therapeutic efficacy of doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res., 55: 2352-2356, 1995.
10. Yeh, M-Y., Roffler, S. R., and Yu, M-H. Doxorubicin. Monoclonal antibody conjugate for therapy of human cervical carcinoma. Int. J. Cancer, 51: 274-282, 1992.
11. Schally, A. V., and Nagy, A. Chemotherapy targeted to hormone receptors on tumors. Eur. J. Endocrinol., in press, 1999.
12. Reubi, J. C., Krenning, E. P., Lamberts, S. W. J., and Kvols, L. In vitro detection of somatostatin receptors in human tumors. Metabolism, 41 (Suppl. 2): 104-110, 1992.
13. Sinisi, A. A., Bellastella, A., Prezioso, D., Nicchio, M. R., Lotti, T., Salvatore, M., and Pasquali, D. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. J. Clin. Endocrinol. Metab., 82: 2566-2569, 1997.
14. Munkelwitz, R. A., Whyard, T. C., Waltzer, W. C., Meek, A. G., and Hod, Y. Expression of somatostatin receptors in human prostatic cell lines. J. Urol., 157 (Suppl. 4): 9, 1997.
15. Brevini, T. A., Bianchi, R., and Motta, M. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. J. Clin. Endocrinol. Metab., 77: 626-631, 1993.
16. Tatoud, R., Degeorges, A., Prevost, G., Hoepffner, J. L., Gauville, C., Millot, G., Thomas, F., and Calvo, F. Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro inhibitory effect of BIM-23014 analog. Mol. Cell. Endocrinol., 113: 195-204, 1995.
17. Pollak, M. N., and Schally, A. V. Mechanism of antineoplastic action of somatostatin analogs. Proc. Soc. Exp. Biol. Med., 217: 143-152, 1998.
18. Pinski, J., Schally, A. V., Halmos, G., and Szepeshazi, K. Effect of somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int. J. Cancer, 55: 963-967, 1993.
19. Reubi, J. C., Waser, B., Schaer, J-C., and Markwalder, R. Somatostatin receptors in human prostate and prostate cancer. J. Clin. Endocrinol. Metab., 80: 2806-2814, 1995.
20. 1]-octreotide scintigraphy. Cancer Res., 55 (Suppl. 23): 5805s-5810s, 1995.
21. Gonzales-Barcena, D., Monila-Ayala, M. A., Cortez-Moralez, A., Vadillo-Buenfil, I., Cardenas-Cornejo, I., Comaru-Schally, A. M., and Schally, A. V. Response to administration of somatostatin analog RC-160 (Vapreotide) in patients with advanced prostatic cancer at relapse time. In: 80th Annual Meeting of the Endocrine Society, New Orleans, LA, June 24-27, 1998, p. 421. , 1998.
22. Maular, C., Richaud, P., Droz, J. P., Jessueld, D., Dufour-Esquerre, F., and Housset, M. Phase I-II study of the somatostatin analog lanreotide in hormone-refractory prostate cancer. Cancer Chem. Pharmacol., 36: 259-262, 1995.
23. 1]-octreotide scintigraphy in patients with hormone-refractory prostatic adenocarcinoma can predict therapy outcome with octreotide treatment: a pilot study. Anticancer Res., 18: 513-516, 1998.
24. Vainas, G., Pasaitou, V., Galactidou, G., Maris, K., Christodoulou, K., Constantinidis, C., and Korsaris, A. H. The role of somatostatin analogs in complete antiandrogen treatment in patients with prostatic carcinoma. J. Exp. Clin. Cancer Res., 16: 119-126, 1997.
25. Thakur, M. L., Kolan, H., Li, J., Wiaderkiwicz, R., Pallela, V. R., Duggaraju, R., and Schally, A. V. Radiolabeled somatostatin analogs in prostate cancer. Nucl. Med. Biol., 24: 105-113, 1997.
26. 3]octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 20: 716-731, 1993.
27. Radulovic, S., Nagy, A., Szöke, B., and Schally, A. V. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett., 62: 263-271, 1992.
28. Nagy, A., Schally, A. V., Halmos, G., Armatis, P., Cai, R-Z., Csernus, V., Kovacs, M., Koppán, M., Szepeshazi, K., and Kahán, Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA, 95: 1794-1799, 1998.
29. Nagy, A., Armatis, P., and Schally, A. V. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1,000 times more potent; structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc. Natl. Acad. Sci. USA, 93: 2464-2469, 1996.
30. Cai, R-Z., Szöke, B., Lu, R., Fu, D., Redding, T. W., and Schally, A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA, 83: 1896-1900, 1986.
31. Koppán, M., Nagy, A., Schally, A. V., Arencibia, J. M., Plonowski, A., and Halmos, G. Targeted cytotoxic analog of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res., 58: 4132-4137, 1998.
32. Taylor, J. E., Theveniau, M. A., Bashirzadeh, R., Reisine, T., and Eden, P. A. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides, 15: 1229-1236, 1994.
33. Stephenson, R. A., Dinney, C. P. N., Gohji, K., Ordonez, N. G., Kilion, J. J., and Fidler, I. J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst., 84: 951-957, 1992.
34. Rembrink, K., Romijn, J. C., van der Kwast, T. H., Rubben, H., and Schroeder, F. H. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate, 31: 168-174, 1997.
35. Garzotto, M., Huryk, R., Fair, W. R., and Heston, W. D. W. Prostatic tumor implantation in the nude mouse via a perineal approach. Prostate, 33: 60-63, 1997.
36. Evans, A. A., Crook, T., Laws, S. A. M., Gough, A. C., Royle, G. T., and Primrose, J. N. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br. J. Cancer, 75: 798-803, 1997.
37. Buscail, L., Delesque, N., Estève, J. P., Saint-Laurent, N., Prats, H., Clerc, P., Robberecht, P., Bell, G. I., Liebow, C., Schally, A. V., Vaysse, N., and Susini, C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogs: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. USA, 91: 2315-2319, 1994.
38. Gordon, A. W., Pegues, J. C., Johnson, G. R., Kannan, B., Auesperg, N., and Stromberg, K. mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. Cancer Lett., 89: 63-71, 1995.
39. Szepeshazi, K., Korkut, E., and Schally, A. V. Decrease in the AgNOR number in Dunning R3327 prostate cancer after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone. Am. J. Pathol., 138: 1273-1277, 1991.
40. Derenzini, M., and Trere, D. Importance of interphase nuclear organizer regions in tumor pathology. Virchows Arch. B. Cell Pathol., 61: 1-8, 1991.
41. Ehrlich, P. The relationship existing between chemical constitution, distribution, and pharmacological action. In: F. Himmelweite, M. Marquadt, and H. Dale (eds.), The Collected Papers of Paul Ehrlich, Vol. 1., pp. 596-618. Elmsford, NY: Pergamon, 1956.
42. Kaighn, M. E., Shankar Narayan, K., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of human prostatic carcinoma cell line (PC-3). Investig. Urol., 17: 16-23, 1979.
43. 188Re-RC-160, a directly labeled somatostatin analog. Int. J. Cancer, 65: 214-220, 1996.
44. Patel, Y. C., and Srikant, C. B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology, 135: 2814-2817, 1994.
45. Denzler, B., and Reubi, J. C. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer (Phila.), 80: 188-198, 1999.
46. 3 derivatives of octreolide in rats. Anticancer Res., 18: 83-90, 1998.
47. Otte, A., Mueller-Brand, J., Dellas, S., Nitsche, E. U., Herrmann, R., and Maecke, H. R. Yttrium-90-labeled somatostatin-analogue for cancer treatment. Lancet, 351: 417-418, 1998.
48. Stolz, B., Smith-Jones, P., Albert, R., Tolcsvai, L., Briner, U., Ruser, G., Mäcke, H., Weckbecker, G., and Bruns, C. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion, 57 (Suppl. 1): 17-21, 1996.
49. Wiseman, G. A., and Kvols, L. K. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin. Nucl. Med., 25: 272-278, 1995.
50. 111In-pentetreotide: initial observations and future directions. Cancer J. Sci. Am., 4: 94-102, 1998.
51. Denmeade, S. R., Lin, X. S., and Isaacs, J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251-265, 1996.
52. Chen, C-T., Au, J. L-S., and Wientjes, M. G. Pharmacodynamics of doxorubicin in human prostate tumors. Clin. Cancer Res., 4: 277-282, 1998.